Phase I/II safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab in metastatic melanoma patients

被引：0

作者：

Johnson, Daniel Johnson H. ^{[1
]}

Lecagoonporn, Srisuda ^{[1
]}

Bernatchez, Chantale ^{[1
]}

Haymaker, Cara ^{[1
]}

Bentebibel, Salah ^{[1
]}

Uemura, Marc ^{[1
]}

Yee, Cassian ^{[1
]}

Amaria, Rodabe ^{[1
]}

Patel, Sapna ^{[1
]}

Tawbi, Hussein ^{[1
]}

Glitza, Isabella ^{[1
]}

Davies, Michael A. ^{[1
]}

Wong, Michael K. ^{[1
]}

Hwu, Wen-Jen ^{[1
]}

Hwu, Patrick ^{[1
]}

Overwijk, Willem ^{[1
]}

Diab, Adi ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P230

引用

页数：1

共 43 条

[41] Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Kim, S-B.
Keam, B.
Shin, S.
Chae, Y. S.
Seo, S.
Park, K.
Kim, T. M.
Park, L. C.
Hong, S-B.
Lim, E.
Lee, S.
Ahn, M-J.
ANNALS OF ONCOLOGY, 2020, 31 : S667 - S668
[42] Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)
Lau, Sai Ping
van 't Land, Freek R.
van der Burg, Sjoerd H.
Homs, Marjolein Y., V
Lolkema, Martijn P.
Aerts, Joachim G. J., V
van Eijck, Casper H. J.
BMJ OPEN, 2022, 12 (06):
[43] First-line-Therapie beim inoperablen oder metastasierten MelanomRandomisierte, offene, multizentrische Phase-I/II-Studie zur Sicherheit und Wirksamkeit einer Triple-Therapie mit dem BRAF-Inhibitor Encorafenib und dem MEK-Inhibitor Binimetinib in Kombination mit dem Anti-PD-1-Antikörper Pembrolizumab bei Patienten mit BRAF-mutiertem MelanomFirst-line therapy for inoperable or metastatic melanomaRandomized, open, multicenter phase I/II study on the safety and efficacy of triple therapy with the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in combination with the anti-PD-1 antibody pembrolizumab in patients with BRAF-mutated melanoma
L. Zimmer
E. Livingstone
D. Schadendorf
Forum, 2020, 35 (2) : 146 - 147

← 1 2 3 4 5 →